Abstract: The present invention relates to methods and compositions for identifying, selecting and/or producing a pathogen resistant plant or germplasm (e.g., soybean plant or germplasm) using genes derived from Glycine tomentella. Candidate genes capable of conferring pathogen resistance (e.g., to Asian Soy Rust) are provided. A plant or germplasm that has been identified, selected and/or produced by any of the methods of the present invention is also provided. Pathogen resistant seeds, plants and germplasms are also provided.

Abstract: Provided are exosomes derived from V?2-T cell (V?2-T-Exos) for killing or inhibiting EBV-infected cells. Further provided is a method for killing or inhibiting the growth of an EBV-infected cell, comprising contacting the EBV-infected cell with exosomes from V?2+ T cells in an amount effective to kill or inhibit the growth of the cell. Preferably, the EBV-infected cell is an EBV-infected cell that has become neoplastic, such as an EBV-infected neoplastic B-cell or an EBV-infected neoplastic epithelial cell. Further provided is a method for treating an EBV-induced cancer in a subject by administering to the subject a therapeutically effective amount of V?2-T-Exos. V?2-T-Exos can be derived from V?2-T cells obtained from the subject or from an allogeneic healthy individual. Methods for isolating V?2-T-Exos from V?2-T cells are also provided.

Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.

Abstract: Aminobisphosphonate pamidronate (PAM) can control Epstein-Barr virus (EBV) associated disorders in humanized mice through a V?9V?2-T-cell dependent mechanism. This suggests a strong potential for a therapeutic approach using PAM to boost human V?9V?2-T-cell immunity against EBV associated disorders, such as the lymphoproliferative disease (LPD), posttransplant lymphoproliferative disorder (PLPD), Hodgkin's disease, Burkitt's lymphoma, and nasopharyngeal carcinoma (NPC).

Abstract: A dual-crankshaft engine includes a piston and two crankshafts constituting a double-crank mechanism, and further includes a cylindrical block. The cylindrical block includes a cylinder portion and a crankshaft support portion. A lower end of the piston is a piston guiding rod. A piston rod guiding groove is provided in the cylindrical block. A lower end of the piston is opened, and provided with a piston end cover. The piston end cover and the piston guiding rod are detachably and fixedly connected. The piston is a non-skirted piston where the piston sealing end is separated from the piston guiding end. The piston sealing end is the piston head of the piston. The piston guiding end is the piston guiding rod and the piston rod guiding groove. The piston is designed to be equi-stress, which increases the strength.

Abstract: An engine cylinder block includes a cylinder block housing and a double-crankshaft mechanism installation case located at a downside of the cylinder block housing. The cylinder block housing is integrally connected with the double-crankshaft mechanism installation case. The cylinder block housing is provided with a cylinder block cavity. The double-crankshaft mechanism installation case is enclosed and formed by an end cover and a side cover. A piston rod guiding groove is installed in the double-crankshaft mechanism installation case. A connecting rod sliding groove is configured through the piston rod guiding groove. A crank operation cavity is configured on both sides of the piston rod guiding groove. A main spindle installation hole is configured on the shell at both ends of each crank operation cavity. A main spindle supporting portion is configured below the main spindle installation hole.

Abstract: A dual-crankshaft engine includes a piston and two crankshafts constituting a double-crank mechanism, and further includes a cylindrical block. The cylindrical block includes a cylinder portion and a crankshaft support portion. A lower end of the piston is a piston guiding rod. A piston rod guiding groove is provided in the cylindrical block. A lower end of the piston is opened, and provided with a piston end cover. The piston end cover and the piston guiding rod are detachably and fixedly connected. The piston is a non-skirted piston where the piston sealing end is separated from the piston guiding end. The piston sealing end is the piston head of the piston. The piston guiding end is the piston guiding rod and the piston rod guiding groove. The piston is designed to be equi-stress, which increases the strength.

Abstract: An engine cylinder block includes a cylinder block housing and a double-crankshaft mechanism installation case located at a downside of the cylinder block housing. The cylinder block housing is integrally connected with the double-crankshaft mechanism installation case. The cylinder block housing is provided with a cylinder block cavity. The double-crankshaft mechanism installation case is enclosed and formed by an end cover and a side cover. A piston rod guiding groove is installed in the double-crankshaft mechanism installation case. A connecting rod sliding groove is configured through the piston rod guiding groove. A crank operation cavity is configured on both sides of the piston rod guiding groove. A main spindle installation hole is configured on the shell at both ends of each crank operation cavity. A main spindle supporting portion is configured below the main spindle installation hole.

Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.

Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.

Abstract: Aminobisphosphonate pamidronate (PAM) can control Epstein-Barr virus (EBV) associated disorders in humanized mice through a V?9V?2-T-cell dependent mechanism. This suggests a strong potential for a therapeutic approach using PAM to boost human V?9V?2-T-cell immunity against EBV associated disorders, such as the lymphoproliferative disease (LPD), posttransplant lymphoproliferative disorder (PLPD), Hodgkin's disease, Burkitt's lymphoma, and nasopharyngeal carcinoma (NPC).

Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.